Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393808 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL7343176 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL11472496 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL6909004 | 1.00 | MEN1 (0.45) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL20063736 | 0.97 | TDP1 (0.43) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL1697382 | 0.97 | TDP1 (0.48) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| Hydrochloric Acid SCHEMBL419829 | 0.97 | TDP1 (0.43) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL20752154 | 0.97 | TDP1 (0.48) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| SCHEMBL21799607 | 0.97 | TDP1 (0.43) | MEN1KMT2ATHRBTDP1CYP2D6 | |
| Hydrochloric Acid SCHEMBL419828 | 0.97 | TDP1 (0.43) | MEN1KMT2ATHRBTDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-5739158-A | Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0594597-A1 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS | G.D. Searle & Co. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0594597-A4 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS. | SEARLE & CO (US) | 1993-04-30 | — | — | EP | disclosed |
| US-5130330-A | Central nervous system disorders, antiischemic agents, psychotic disorders and anticonvulsants | G. D. SEARLE & CO. (US) | 1992-07-14 | — | — | US | disclosed |
| WO-1991012247-A1 | NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS | G.D. SEARLE & CO. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0248824-B1 | USE OF CIS-N-(2 AMINOCYCLOALIPHATIC) BENZENE ACETAMIDE AND BENZAMIDE FOR THE MANUFACTURE OF ANTICONVULSANTS | THE UPJOHN COMPANY (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4801604-A | REDUCED ANALGESIC PROPERTIES | THE UPJOHN COMPANY (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0248824-A1 | Use of CIS-N-(2 Aminocycloaliphatic) benzene acetamide and Benzamide for the manufacture of anticonvulsants. | UPJOHN CO (US) | 1987-12-16 | — | — | EP | disclosed |
| EP-0222533-A1 | Cis-N-[(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants | THE UPJOHN COMPANY (US) | 1987-05-20 | — | — | EP | disclosed |
| WO-1987002584-A1 | CIS-N-(2-AMINOCYCLOALIPHATIC)BENZENE ACETAMIDE AND -BENZAMIDE ANTICONVULSANTS | THE UPJOHN COMPANY (US) | 1987-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | MEN1 3066/4885KMT2A 2104/4885THRB 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.